Nasal congestion with iloperidone therapy in a case series.
نویسندگان
چکیده
Iloperidone or 40-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-30-methoxyacetophenone is an atypical psychotropic agent belonging to piperidinyl-benzisoxazole derivative, having marked antagonistic actions on adrenergic, serotonergic, and dopaminergic receptors. It is an excellent emerging drug in anxiety and schizophrenia, and particularly useful in acute stages due to involvement of single nucleotide polymorphism in action. Iloperidone is metabolized primarily by 3 biotransformation pathways: carbonyl reduction, hydroxylation (mediated by CYP2D6) and O-demethylation (mediated by CYP3A4). There are 2 predominant iloperidone metabolites, P95 and P88, having a higher plasma concentration comparedwith the parent compound. The half lives of these metabolites, drug concentration in plasma and toxicities vary in fast and slow metabolizers of CYP2D6. Iloperidone is fairly well tolerated. Orthostatic hypotension, somnolence and dizziness are frequently reported apart from fatigue, dry mouth, tachycardia, nasal congestion, hyperprolactinemia, weight gain and hypoglycemia. Other rare adverse effects include QT interval prolongation, leucopenia, neutropenia, agranulocytosis, Neuroleptic Malignant Syndrome (NMS), priapism, suicide and cognitive and motor impairment. However, extra pyramidal symptoms are less.1,2 Here we present an interesting case series of iloperidone induced nasal congestion among 23 patients (17–39 years), out of 57, who were diagnosed schizophrenic and presented in a psychiatry outpatient department in Kolkata, and treated with iloperidone. Initial dose of the drug ranged between 1 and 2 mg twice daily, whichwere gradually titrated up to 12mg twice daily. Interestingly, 23 patients presented with intense nasal congestion and headache between 20 and 35 days of taking the escalated dose (Table 1). However, each of them reported to have excellent control of schizophrenic symptoms. There were no evidences of any co-existing pathological conditions or history of concomitant medications in any patients. Neither of them complained of nasal congestion or headache before initiating iloperidone. Routine blood investigations done in 10 patients were well within normal limits. X-ray of para nasal sinuses done in 11 patients and CT scan of brain done in 3 failed to prove the presence of co-existing sinusitis or other associated pathologies. For excellent therapeutic responses to schizophrenia, the drug was not withdrawn. Those patients with nasal congestion were symptomatically treated with steam inhalation, oral paracetamol and oxymetazoline nasal drops with very good responses. Some other side effects of iloperidone were also manifested. 8 patients experienced postural hypotension, 10 had fatigue and dizziness, 4 had dry mouth and somnolence, 4 others had some weight gain, 3 had tachycardia and 2 subjects experienced mild hypoglycemia after taking the drug for at least 4 weeks. But nasal congestion was the most extensive and frequent complaint (23/57 or 40.35%). A pooled analysis of 3 double blind, multicenter, placebo and active controlled phase III clinical trials of Potkin et al found that iloperidone was effective in schizophrenia.3 A pooled analysis of safety data by Weiden et al from those 3 trials demonstrated the common reported adverse effects of iloperidone as dizzinness, dry mouth, somnolence and dyspepsia. Extra pyramidal symptoms were rather improved with iloperidone. Patients taking iloperidone showed an akathisia profile similar to placebo and weight gain similar to risperidone. QT interval increased significantly but was not associated with significant change in total serum cholesterol. Iloperidone was associated with significant increase in serum glucose and decrease in triglyceride levels. However, prolactin levels were decreased with iloperidone and increased with haloperidol and risperidone.4 A randomized, double blind, placebo and active controlled, multicenter 4-week study by Cutler et al proved the superior efficacy of iloperidone in schizophrenia compared to placebo and ziprasidone. Most adverse events with iloperidone included dizziness, sedation, weight increase, tachycardia, nasal congestion and orthostatic hypotension. Iloperidone was associated with lower rates of sedation, somnolence, extra pyramidal symptoms, akathisia, and restlessness. Significant increases in QT interval occurred in both ziprasidone and iloperidone. Mean changes in total cholesterol, triglycerides, glucose, and prolactin were similar between treatment groups. However, iloperidone was associated with higher rates of weight gain, tachycardia, orthostatic hypotension, dizziness, and nasal congestion.5 A pooled analysis from 3 randomized, double blind, multicenter, flexible dose 1 year studies by Kane et al compared iloperidone with haloperidol in schizophrenic patients and found no significant differences in time to relapse between these 2 drugs. The common adverse events with iloperidonewere insomnia, nasal
منابع مشابه
New Drugs Drug News
NEW DRUGS Iloperidone (Fanapt) For Schizophrenia The FDA has approved iloperidone tablets (Fanapt, Patheon/Vanda) for adults with schizophrenia. Symptoms of this illness include auditory hallucinations, delusions, disordered thinking and behavior, and abnormal expression of emotions. Schizophrenia affects about 1% of adults 18 years of age and older in the U.S. each year. An atypical antipsycho...
متن کاملروشهای درمانی سینوزیت قارچی مهاجمManagement & Treatment of Invasive Fungal Sinusitis
Background & Aim: Invasive fungal sinusitis is an opportunistic infection by aspergilosis and mucoracae, but mucoracae is more common than aspergilosis. Mucormycosis is an acute opportunistic fungal infection mostly seen with an underlying disease. It has different clinical presentations such as rhinocerebral and orbital involvement, which are very aggressive and with high mortality rate. T...
متن کاملComputational Investigation on the Effect of Changes in Halogenated on Afrin with Fullerene
In this research at the first Afrin drug or and its fullerene derivative were optimized. Afrin is a nasal congestion drug that acts by contraction of the blood vessels of the arteries and veins. Afrin acts directly on the nasal vessels. Eclipse of the blood vessels in your nose and the sinuses causes the water to be collected and the nasal congestion is reduced. And this medicine is used for co...
متن کاملBreast Cancer Associated with Dermatomyositis
Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy with characteristic skin lesions. Case series have shown an association between dermatomyositis and malignancy. Malignancy has been found in 15-25% of the adult patients with dermatomyositis. A 50-year-old new case of breast cancer, was admitted with muscle weakness and inability to walk. Physical examination revealed fever, perior...
متن کاملدرمان زودرس با Nasal CPAP در نوزادان نارس با سندرم دیسترس تنفسی
Background: Respiratory distress syndrome (RDS) is a major cause of mortality among premature neonates. The present study was conducted to find out whether early nasal CPAP therapy could eliminate the need for mechanical ventilation in premature neonates with RDS. Materials and methods: For this clinical trial, premature neonates with RDS during the first 6 hours following the delivery were as...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of young pharmacists : JYP
دوره 5 3 شماره
صفحات -
تاریخ انتشار 2013